Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Share News (OVB)

Share Price Information for Ovoca Bio (OVB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.90
Bid: 0.80
Ask: 1.00
Change: 0.00 (0.00%)
Spread: 0.20 (25.00%)
Open: 0.90
High: 0.90
Low: 0.845
Prev. Close: 0.90
OVB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Strong annual results from Springfield, Fiske

Tue, 14th Sep 2021 17:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Springfield Properties PLC - Scottish housebuilder - For the year ended May 31, pretax profit rises 81% to GBP18.5 million from GBP10.2 million, on revenue growing 51% year-on-year to GBP216.7 million from GBP143.5 million, driven by higher sales and demand in private and affordable housing. Total completes increases to 973 homes from 727, as the average selling price for private housing rises to GBP244,000 from GBP236,000. Declares dividend of 5.75 pence, more than doubled from 2.0p the prior year.

----------

Harworth Group PLC - Rotherham, Yorkshire-based land regenerator - For the six months ended June 30, swings to pretax profit of GBP80.1 million from loss of GBP3.7 million, due to revaluation gains on properties and assets of GBP105.7 million. In addition, revenue declined 20% year-on-year to GBP18.9 million from GBP23.7 million due to later starts on site in 2020 due to the pandemic. As at June 30, net asset value per share was 167.8p, up from 142.2p the same date the year prior, while the portfolio value stands at GBP748.0 million from GBP618.2 million at the end of December. Declares interim dividend of 0.36 pence per share, up from 0.33p a year prior.

----------

Aberdeen Smaller Companies Income Trust PLC - invests in UK small-cap stocks - Net asset value total return for the six months ended June 30 was 20.1%, compared to the Numis Smaller Companies excluding Investment Trust index, which returned 17.4%. As at June 30, NAV per share is 413.97 pence, up 19% from 348.91p at the end of December.

----------

Henderson High Income Trust PLC - pure income trust investing in dividend-paying UK companies - For the first half of 2021, net asset value total return was 12.3%, while its benchmark - a composite made up 80% of the FTSE All-Share index and 20% of the ICE BofAML Sterling Non-Gilts index - returned 8.4%. At the end of June, NAV per share was 171.6 pence, up % from 157.3p at December 31.

----------

Phoenix Global Resources PLC - upstream oil and gas company - For the first half of 2021, pretax loss narrows to USD3.9 million from USD62.1 million the same period a year before, on revenue which grows 45% year-on-year to USD36.1 million from USD24.9 million. Revenue growth was due to higher oil sales during the period, mainly through the shut-in of production due to Covid-19 in 2020 and the rise in oil prices to USD47.03 per barrel to USD39.19.

----------

Infrastructure India PLC - investor in infrastructure assets in India's energy and transport sectors - Renewable assets are currently operating in line with expectations due to steady demand for power. As at August 31, cash position stands at USD3.5 million, and the company continues to evaluate options and find alternative sources of financing. As at March 31, expects to report net asset value per share between 10p to 13p. Applies to AIM for three-month extension for its annual results, which is expected to be published in October.

----------

ThinkSmart Ltd - Australian digital payments platform - For the year ended June 30, pretax profit rises 35% to GBP71.7 million from GBP53.1 million the year before, mainly due to a higher gain on financial instruments on the revaluation of the group's investment in ClearPay Finance Ltd due to a strong performance from the investee. However, revenue dropped 31% year-on-year to GBP4.3 million from GBP6.3 million on a drop in leasing volumes.

----------

Porvair PLC - Norfolk, England-based filtration and environmental technology firm - Trading for the third quarter ended August 31 is ahead of expectations, with healthy order books in industrial processes, laboratory and aluminium. However, due to supply chain issues, company has deemed it too early to determine its annual performance.

----------

Good Energy Group PLC - Chippenham, England-based energy company - For the first half of 2021, swings to pretax profit of GBP4.8 million from loss of GBP1.1 million the same period a year before, on revenue which rises 1.4% year-on-year to GBP68.4 million from GBP67.5 million on an increase in customer numbers. Intends to recommend a dividend payment for 2021, and will pay 0.75p per share should the hostile offer by Ecotricity Group Ltd lapse or be withdrawn.

----------

Ovoca Bio PLC - Women's health-focused biopharmaceutical company - For the six months ended June 30, pretax loss widens to USD3.7 million from USD2.2 million a year before, due to a rise in administrative expenses and the generation of no revenue during the period.

----------

Kistos PLC - London-based energy sector investor - For the 37 weeks ended June 30, reports pretax loss of EUR5.2 million, on revenue of EUR6.6 million. On a proforma basis following the acquisition of Tulip Oil Netherlands BV, revenue rose 97% year-on-year to EUR33.7 million from EUR17.1 million. despite production falling 28% to 1,598 megawatt hours from 2,230MWh.

----------

MaxCyte Inc - Maryland, US-based biotechnology company - For the first half of 2021, net loss widens to USD11.5 million from USD6.1 million the year before, due to higher operating expenses through an increased headcount and higher stock-based compensation, as well as a rise in legal expenses. Meanwhile, revenue grows 25% to USD13.6 million from USD10.9 million, through higher sales in cell therapy and drug discovery markets.

----------

Property Franchise Group PLC - UK-based lettings and estate agency franchising firm - For the six months ended June 30, pretax profit rises 57% to GBP3.1 million from GBP2.0 million the same period a year prior, as well as a 54% increase from the first half of 2019. This is on revenue which more than doubles to GBP11.1 million from GBP5.1 million, on higher managed services fees and increased sales activity. Raises interim dividend by 81% to 3.8 pence from 2.1p. Looking ahead, expects 2021 annual profit performance to be ahead of market expectations.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - For the year ended June 30, pretax loss widens to GBP11.5 million from GBP5.3 million the year before due to higher expenses as the company sets up key studies designed to increased the value of Diurnal's pipeline. Revenue declines % year-on-year to GBP4.4 million from GBP6.3 million, driven by a drop in product sales and licensing income.

----------

Made.com Group PLC - London-based furniture retailer - For the six months ended June 30, pretax loss narrows to GBP10.1 million from GBP15.2 million, as revenue grows 61% year-on-year to GBP171.0 million from GBP106.3 million, driven by a 54% increase in gross sales to GBP213.9 million supported by high levels of market demand. Looking ahead, revenue for 2021 is expects to be around GBP410 million, reflecting a 65% increase.

----------

Fiske PLC - London-based stockbroker and investment manager - For the year ended May 31, pretax profit is GBP610,000, swinging from a loss of GBP127,000 the year before, on revenue which grows 13% year-on-year to GBP6.1 million from GBP5.4 million.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Oct 2020 10:54

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Read more
2 Oct 2020 10:10

Ovoca Bio hits stumbling block in Russia drug approval

(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
21 Sep 2020 21:19

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

Read more
26 Jun 2020 11:58

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Read more
24 Mar 2020 18:39

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Read more
16 Sep 2019 11:33

Ovoca Bio narrows losses as BP-101 trials continue

(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual dysfunction.

Read more
16 Sep 2019 10:48

Ovoca Bio Interim Loss Widens On Administration Expenses

(Alliance News) - Ovoca Bio PLC on Monday said its loss widened in the first half of the year, suffering higher administration expenses in the year as it worked to develop its BP-101 female sexual

Read more
28 Aug 2019 14:43

Ovoca Bio Non-Executive Nikolay Myasoyedov Leaves For Personal Reasons

(Alliance News) - Ovoca Bio PLC on Wednesday said Non-Executive Director Nikolay Myasoyedov intends to step down from the board with immediate effect for personal reasons.The pharmaceutical

Read more
8 Aug 2019 11:24

Ovoca Bio's Libicore Application Result Expected A Year After Filing

(Alliance News) - Ovoca Bio PLC on Thursday said it intends to file for the approval of its Libicore female sexual dysfunction drug later in the quarter and expects the verdict in a year's 16%

Read more
26 Jul 2019 17:03

Ovoca Bio Says Non-Executive Director Yuri Radchenko Has Left Role

(Alliance News) - Drug company Ovoca Bio PLC said on Friday Yuri Radchenko, a non-executive director, has stepped down with immediate effect due to personal reasons.Chief Executive Kirill I

Read more
28 Jun 2019 15:07

Ovoca Bio Loss Widens; Prepares For Market Approval Filing For Libicore

(Alliance News) - Ovoca Bio PLC on Friday said its annual loss widened heavily as a result of administration expenses and said it is preparing to file for marketing approval of its drug BP101 in a

Read more
23 Apr 2019 15:40

Ovoca Bio's IVIX ropes in Biorasi for development of 'Libicore' drug candidate

(Sharecast News) - Ovoca Bio announced on Tuesday that its subsidiary IVIX has begun the process of preparing an integrated clinical development plan for its investigational drug candidate, 'Libicore' (BP-101), for both the US and EU regions with US-based contract research organisation Biorasi.

Read more
27 Mar 2019 10:21

Ovoca Bio Expands IVIX Stake Amid Strong Libicore Drug Trial Results

LONDON (Alliance News) - Ovoca Bio PLC said Wednesday it increased its stake in a majority-owned subsidiary following a positive set of test results from its Libicore sexual desire - known as Gold

Read more
25 Mar 2019 12:13

Ovoca Bio To Seek Russian Approval For Libicore After Successful Trial

LONDON (Alliance News) - Ovoca Bio PLC on Monday said it intends to file for the approval of its hypoactive sexual desire disorder drug Libicore in Russia after positive results from a recent in a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.